4D Molecular Therapeutics's market cap is currently ―. The company's EPS TTM is $-2.734; its P/E ratio is -9.65; 4D Molecular Therapeutics is scheduled to report earnings on May 9, 2024, and the estimated EPS forecast is $-0.74. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	$ -18.00K	$ 20.20M	$ 239.00K	$ 298.00K	$ 1.25M
Gross Profit	$ -18.00K	$ 20.20M	$ 239.00K	$ 298.00K	$ 1.25M
EBIT	$ -32.28M	$ -10.26M	$ -29.62M	$ -30.13M	$ -28.72M
EBITDA	$ -31.25M	-	$ -28.41M	$ -29.11M	$ -27.56M
Net Income Common Stockholders	$ -32.28M	$ -10.26M	$ -29.62M	$ -28.68M	$ -27.38M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 288.23M	$ 319.66M	$ 310.34M	$ 200.45M	$ 213.55M
Total Assets	$ 339.89M	$ 361.61M	$ 352.50M	$ 244.02M	$ 261.85M
Total Debt	$ 14.67M	$ 15.16M	$ 15.63M	$ 15.68M	$ 16.12M
Net Debt	$ -273.56M	$ -304.51M	$ -294.71M	$ -184.77M	$ -197.43M
Total Liabilities	$ 32.06M	$ 31.68M	$ 27.36M	$ 25.41M	$ 30.51M
Stockholders Equity	$ 307.83M	$ 329.93M	$ 325.13M	$ 218.61M	$ 231.34M
Cash Flow	-
Free Cash Flow	$ -25.20M	-	$ -22.87M	$ -28.92M	$ -23.31M
Operating Cash Flow	$ -24.65M	$ -1.17M	$ -22.07M	$ -27.91M	$ -22.21M
Investing Cash Flow	$ -6.68M	$ 29.98M	$ 49.29M	$ 43.13M	$ -35.78M
Financing Cash Flow	$ 4.76M	$ 10.56M	$ 130.52M	$ 10.99M	$ 2.05M

Currency in USD

4D Molecular Therapeutics Earnings and Revenue History

Income Statement >

4D Molecular Therapeutics Debt to Assets

Balance Sheet >

4D Molecular Therapeutics Cash Flow

Cash Flow >

4D Molecular Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing